Annual EBITDA
-$43.27 M
+$21.30 M+32.98%
December 31, 2023
Summary
- As of February 8, 2025, TARA annual EBITDA is -$43.27 million, with the most recent change of +$21.30 million (+32.98%) on December 31, 2023.
- During the last 3 years, TARA annual EBITDA has fallen by -$9.43 million (-27.87%).
- TARA annual EBITDA is now -453.78% below its all-time high of -$7.81 million, reached on December 31, 2019.
Performance
TARA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$12.25 M
-$1.67 M-15.77%
September 30, 2024
Summary
- As of February 8, 2025, TARA quarterly EBITDA is -$12.25 million, with the most recent change of -$1.67 million (-15.77%) on September 30, 2024.
- Over the past year, TARA quarterly EBITDA has dropped by -$1.63 million (-15.30%).
- TARA quarterly EBITDA is now -757.14% below its all-time high of -$1.43 million, reached on June 30, 2019.
Performance
TARA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$45.53 M
-$1.63 M-3.70%
September 30, 2024
Summary
- As of February 8, 2025, TARA TTM EBITDA is -$45.53 million, with the most recent change of -$1.63 million (-3.70%) on September 30, 2024.
- Over the past year, TARA TTM EBITDA has increased by +$25.60 million (+35.99%).
- TARA TTM EBITDA is now -3086.53% below its all-time high of -$1.43 million, reached on June 30, 2019.
Performance
TARA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TARA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +33.0% | -15.3% | +36.0% |
| 3 y3 years | -27.9% | -15.3% | +36.0% |
| 5 y5 years | -103.6% | -15.3% | +36.0% |
TARA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +33.0% | -66.5% | +68.4% | -28.1% | +36.0% |
| 5 y | 5-year | -453.8% | +33.0% | -389.2% | +68.4% | -624.2% | +36.0% |
| alltime | all time | -453.8% | +33.0% | -757.1% | +68.4% | -3086.5% | +36.0% |
Protara Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.25 M(+15.8%) | -$45.53 M(+3.7%) |
| Jun 2024 | - | -$10.58 M(-10.1%) | -$43.90 M(-3.3%) |
| Mar 2024 | - | -$11.77 M(+7.6%) | -$45.38 M(+4.9%) |
| Dec 2023 | -$43.27 M(-33.0%) | -$10.93 M(+2.9%) | -$43.27 M(-39.2%) |
| Sep 2023 | - | -$10.62 M(-11.9%) | -$71.12 M(+4.8%) |
| Jun 2023 | - | -$12.06 M(+24.9%) | -$67.86 M(+6.1%) |
| Mar 2023 | - | -$9.65 M(-75.1%) | -$63.93 M(-1.0%) |
| Dec 2022 | -$64.57 M(+42.2%) | -$38.78 M(+427.5%) | -$64.57 M(+81.6%) |
| Sep 2022 | - | -$7.35 M(-9.7%) | -$35.55 M(-5.9%) |
| Jun 2022 | - | -$8.14 M(-20.9%) | -$37.80 M(-9.8%) |
| Mar 2022 | - | -$10.29 M(+5.3%) | -$41.88 M(-6.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$45.40 M(+34.2%) | -$9.77 M(+1.8%) | -$44.74 M(+3.1%) |
| Sep 2021 | - | -$9.60 M(-21.5%) | -$43.40 M(+3.7%) |
| Jun 2021 | - | -$12.22 M(-7.0%) | -$41.84 M(+13.4%) |
| Mar 2021 | - | -$13.15 M(+56.1%) | -$36.88 M(+9.0%) |
| Dec 2020 | -$33.84 M(+333.1%) | -$8.43 M(+4.9%) | -$33.84 M(+21.2%) |
| Sep 2020 | - | -$8.04 M(+10.6%) | -$27.91 M(+25.6%) |
| Jun 2020 | - | -$7.27 M(-28.1%) | -$22.23 M(+35.6%) |
| Mar 2020 | - | -$10.11 M(+303.9%) | -$16.40 M(+160.8%) |
| Dec 2019 | -$7.81 M(-63.2%) | -$2.50 M(+6.3%) | -$6.29 M(+66.2%) |
| Sep 2019 | - | -$2.35 M(+64.8%) | -$3.78 M(+164.8%) |
| Jun 2019 | - | -$1.43 M | -$1.43 M |
| Dec 2018 | -$21.26 M | - | - |
FAQ
- What is Protara Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Protara Therapeutics?
- What is Protara Therapeutics annual EBITDA year-on-year change?
- What is Protara Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Protara Therapeutics?
- What is Protara Therapeutics quarterly EBITDA year-on-year change?
- What is Protara Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Protara Therapeutics?
- What is Protara Therapeutics TTM EBITDA year-on-year change?
What is Protara Therapeutics annual EBITDA?
The current annual EBITDA of TARA is -$43.27 M
What is the all time high annual EBITDA for Protara Therapeutics?
Protara Therapeutics all-time high annual EBITDA is -$7.81 M
What is Protara Therapeutics annual EBITDA year-on-year change?
Over the past year, TARA annual EBITDA has changed by +$21.30 M (+32.98%)
What is Protara Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TARA is -$12.25 M
What is the all time high quarterly EBITDA for Protara Therapeutics?
Protara Therapeutics all-time high quarterly EBITDA is -$1.43 M
What is Protara Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TARA quarterly EBITDA has changed by -$1.63 M (-15.30%)
What is Protara Therapeutics TTM EBITDA?
The current TTM EBITDA of TARA is -$45.53 M
What is the all time high TTM EBITDA for Protara Therapeutics?
Protara Therapeutics all-time high TTM EBITDA is -$1.43 M
What is Protara Therapeutics TTM EBITDA year-on-year change?
Over the past year, TARA TTM EBITDA has changed by +$25.60 M (+35.99%)